Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study

Veterinary and Comparative Oncology

Volumn 8, Issue 3, 2010, Pages 188-195

  Lori, J C ^a   Stein, T J ^b   Thamm, D H ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Adriamycin; Cancer; Chemotherapy; Cytoxan; Dog

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYCLOPHOSPHAMIDE; DOXORUBICIN; PLACEBO; PREDNISONE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOG; DOG DISEASE; FEMALE; LYMPHOMA; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOG DISEASES; DOGS; DOXORUBICIN; FEMALE; LYMPHOMA; MALE; NEOPLASM STAGING; PLACEBOS; PREDNISONE; PROGNOSIS; SCHOOLS, VETERINARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 77955263075     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00215.x     Document Type: Article

References (22)

1. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002, 16:704-709.
2. Keller E, MacEwen E, Rosenthal R. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. Journal of Veterinary Internal Medicine 1993, 7:289-295.
3. Chun R, Garrett LD, Vail DM. Cancer chemotherapy. Withrow and MacEwen's Small Animal Clinical Oncology 2007, 163-191. In:, 4th edn, St Louis, Saunders
4. Langer S, Sehested M, Jensen P. Treatment of anthracycline extravasation with dexrazoxane. Clinical Cancer Research 2000, 6:3680-3686.
5. Cvetkovic R, Scott L. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005, 65:1005-1024.
6. Mauldin GE, Fox PR, Patnaik AK, Bond BR, Mooney SC, Matus RE. Doxorubicin-induced cardiotoxicosis. Journal of Veterinary Internal Medicine 1992, 6:82-88.
7. Vail DM, Young KM. Canine lymphoma and lymphoid leukemia. Withrow & MacEwen's Small Animal Clinical Oncology 2007, 699-733. In:, 4th edn, St Louis, Saunders
8. Carter R, Harris C, Withrow SJ. Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. Journal of the American Animal Hospital Association 1987, 23:587-596.
9. Postorino NC, Susaneck SJ, Withrow SJ, Macy DW, Harris C. Single agent therapy with adriamycin for canine lymphosarcoma. Journal of the American Animal Hospital Association 1989, 25:221-225.
10. Mutsaers AJ, Glickman NW, DeNicola DB, Widmer WR, Bonney PL, Hahn KA, Knapp DW. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. Journal of the American Veterinary Medical Association 2002, 220:1813-1817.
11. Valerius K, Ogilvie G, Mallinckrodt C, Getzy D. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). Journal of the American Veterinary Medical Association 1997, 210:512-516.
12. Charney S, Bergman P, Hohenhaus A, Mcknight J. Risk factors for sterile hemorrhagic cystits in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). Journal of the American Veterinary Medical Association 2003, 222:1388-1393.
13. Crow S, Theilen G, Madewell B, Weller RE, Henness AM. Cyclophosphamide induced cystitis in the dog and cat. Journal of the American Veterinary Medical Association 1977, 171:259-262.
14. Stanton M, Legendre A. Effects of cyclophosphamide in dogs and cats. Journal of the American Veterinary Medical Association 1986, 188:1319-1322.
15. Peterson J, Couto C, Hammer A, Ayl AD. Acute sterile hemorrhagic cystitis after single intravenous administration of cyclophosphamide in three dogs. Journal of the American Veterinary Medical Association 1992, 201:1572-1573.
16. Price GS, Page RL, Fischer BM, Levine JF, Gerig TM. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. Journal of Veterinary Internal Medicine 1991, 5:259-262.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000, 92:205-216.
18. Veterinary co-operative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. Veterinary and Comparative Oncology 2004, 2:195-213.
19. Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus B, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, Fridland A, Lee WA, Plunkett W, Vail D, Thamm DH, Jeraj R, Tumas DB. GS-9219-a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clinical Cancer Research 2008, 14:2824-2832.
20. Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clinical Cancer Research 2009, 15:3503-3510.
21. Baldi B, Moore DS. Inference in practice: the power of a statistical test. The Practice of Statistics in the Life Sciences 2009, 398-405. Bleyer C, In:, ed., New York City, W. H. Freeman and Company
22. Minow R, Benjamin R, Lee E, Gottlieb J. Adriamycin cardiomyopathy-risk factors. Cancer 1977, 39:1397-1402.